1. Ventura SJ, Martin JA, Curtin SC, Menacker F, Hamilton BE. Births: final data for 1999. Nat Vital Stat Rep. 2001;49:1-100.
2. American College of Obstetricians and Gynecologists. Assessment of risk for preterm birth. ACOG Practice Bulletin #31. Washington, DC: ACOG; October 2001.
3. American College of Obstetricians and Gynecologists. Preterm labor. ACOG Technical Bulletin #206. Washington, DC: ACOG; June 1995.
4. American College of Obstetricians and Gynecologists. Home uterineactivity monitoring. ACOG Committee Opinion #172. Washington, DC: ACOG; May 1996.
5. American College of Obstetricians and Gynecologists. SalEst’ as a predictor of risk for preterm labor. ACOG Committee Opinion #251. Washington, DC: ACOG; January 2001.
6. American College of Obstetricians and Gynecologists. Fetal fibronectin preterm labor risk test. ACOG Committee Opinion #187. Washington, DC: ACOG; September 1997.
7. American College of Obstetricians and Gynecologists. Bacterial vaginosis screening for prevention of preterm delivery. ACOG Committee Opinion #198. Washington, DC: ACOG; February 1998.
8. Iams JD, Johnson FF, O’Shaughnessy RW. A prospective random trial of home uterine activity monitoring in pregnancies at increased risk of preterm labor. Am J Obstet Gynecol. 1988;159:595-603.
9. Grimes DA, et al. Randomized controlled trials of home uterine activity monitoring: a review and critique. Obstet Gynecol. 1992;79:137-142.
10. Sachs BP, Hellerstein S, Freeman R, et al. Home monitoring of uterine activity. Does it prevent prematurity? N Engl J Med. 1991;325:1374-1377.
11. US. Preventative Services Task Force. Home uterine activity monitoring for preterm labor. Review article. JAMA. 1993;270:371-376.
12. Hanssens MC, Selby C, Symonds EM. Sex steroid hormone concentrations in preterm labour and the outcome of treatment with ritodrine. Br J Obstet Gynaecol. 1985;92:698-702.
13. Goodwin TM. A role for estriol in human labor, term and preterm. Am J Obstet Gynecol. 1999;180:S208-213.
14. Norwitz ER, et al. The control of labor. N Engl J Med. 1999;341:660-666.
15. Voss HF. Saliva as a fluid for measurement of estriol levels. Am J Obstet Gynecol. 1999;180:S226-231.
16. McGregor JA, Jackson GM, Lachlin GC, et al. Salivary estriol as risk assessment for preterm labor: a prospective trial. Am J Obstet Gynecol. 1995;173:1337-1342.
17. Heine RP, McGregor JA, Dullien VK. Accuracy of salivary estriol testing compared to traditional risk factor assessment in predicting preterm birth. Am J Obstet Gynecol. 1999;180:S214-218.
18. McGregor JA, et al. Diurnal variation in salivary estriol level during pregnancy: a pilot study. Am J Obstet Gynecol. 1999;180:S223-225.
19. Hendershott CM, Dullien V, Goodwin TM. Serial betamethasone administration: effect on maternal salivary estriol levels. Am J Obstet Gynecol. 1999;180:S219-222.
20. Goldenberg RL, et al. The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Network. Am J Obstet Gynecol. 2000;182:631-635.
21. Berg AO. Screening for bacterial vaginosis in pregnancy. Recommendations and rationale. Am J Prev Med. 2001;20:59-61.
22. Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy (Cochrane Review). In: The Cochrane Library. Issue 2, 2001. Oxford: Update Software.
23. Morales WJ, et al. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol. 1994;171:345-347.
24. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333:1732-1736.
25. McGregor JA, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol. 1994;170:1048-1059.
26. Creasy RK, Gummer BA, Liggins GC. System for predicting spontaneous preterm birth. Am J Obstet Gynecol. 1980;55:692-695.
27. Mercer BM, et al. The preterm prediction study: a clinical risk assessment system. Am J Obstet Gynecol. 1996;174:1885-1893.
28. Norwitz ER, Repke JT, Greene M. Cervical cerclage—elective and emergent. ACOG Update. 1999;24:1-11.
29. Mortensen OA, Franklin J, Lofstrand T, et al. Prediction of preterm birth. Acta Obstet Gynecol Scand. 1987;66:507-511.
30. Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med. 1996;334:567-572.
31. Heath VCF, Southall TR, Souka AP, et al. Cervical length at 23 weeks of gestation: prediction of spontaneous preterm delivery. Ultrasound Obstet Gynaecol. 1998;12:312-317.
32. SOGC Clinical Practice Guidelines 102: Ultrasound Cervical Assessment in Predicting Preterm Birth Ottawa, Ontario: Society of Obstetricians and Gynaecologists of Canada; 2001.
33. Lockwood CJ, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med. 1991;325:669-674.
34. Goldenberg RL, et al. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. Obstet Gynecol. 1996;87:643-648.
35. Iams JD, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol. 1995;173:141-145.
36. Kurtzman JT, et al. Transvaginal versus transperineal ultrasonography: a blinded comparison in the assessment of cervical length at midgestation. Am J Obstet Gynecol. 1998;179:852-857.
37. Okitsu O, et al. Early prediction of preterm delivery by transvaginal ultrasonography. Ultrasound Obstet Gynecol. 1992;2:402-405.
38. Leituch H, Brunbauer M, Kaider A, Egarter C, Husslein P. Cervical length and dilatation of the internal cervical os detected by vaginal ultrasonography as markers for preterm delivery: a systematic review. Am J Obstet Gynecol. 1999;181:1465-1472.
39. Iams JD, Paraskos J, Landon MB, Teteris JN, Johnson FF. Cervical sonography in preterm labor. Obstet Gynecol. 1994;84:40-46.
40. Guzman ER, Rosenberg JC, Houlihan C, et al. A new method using vaginal ultrasound and transfundal pressure to evaluate the asymptomatic incompetent cervix. Obstet Gynecol. 1994;83:248-252.
41. Guzman ER, Vintzileos AM, McLean DA, et al. The natural history of a positive response to transfundal pressure in women at risk for cervical incompetence. Am J Obstet Gynecol. 1997;176:634-638.
42. Yost NP, et al. Pitfalls in ultrasonic cervical length measurement for predicting preterm birth. Obstet Gynecol. 1999;93:510-516.
43. Arabin B, et al. Maternal position and ultrasonic cervical assessment in multiple pregnancy. J Reprod Med. 1997;42:719-724.
44. Iams JD, Goldenberg RL, Mercer BM, et al. The preterm prediction study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Network. Am J Obstet Gynecol. 1998;178:1035-1040.
45. Goldenberg RL, et al. The preterm prediction study: patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Network. Am J Obstet Gynecol. 1997;177:8-12.
46. Joffe GM, et al. Impact of the fetal fibronectin assay on admission for preterm labor. Am J Obstet Gynecol. 1999;180:581-586.
47. Giles W, Bisits A, Knox M, Madsen G, Smith R. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol. 2000;182:439-442.
48. Mercer BM, et al. Antimicrobial therapy in expectant management of P-PROM. Lancet. 1995;346:1271-1279.
49. Locksmith G, Duff P. Infection, antibiotics, and preterm delivery. Seminars in Perinatology. 2001;25:295-309.
50. Allen SR. Tocolytic therapy in preterm PROM. Clin Obstet Gynecol. 1998;41:842-848.